CIRM Funded Clinical Trials

AB-205-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-205


Edward Kavalerchik
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$6,192,579
Trial Stage: 
Phase 1
Trial Status: 
Launching
Targeted Enrollment:
N/A
Details: 

Angiocrine Bioscience Inc. will use genetically engineered cells, derived from cord blood, to see if they can help alleviate or accelerate recovery from the toxic side effects of chemotherapy for people undergoing treatment for lymphoma and other aggressive cancers of the blood or lymph system.

Design: 

First in human, Phase 1, multi-center trial

Goal: 

Safety